REFLATE TB2, NCT02273765: Raltegravir Versus Efavirenz in Naive HIV-1-infected Patients Receiving Rifampin for Active Tuberculosis |
|
|
| Completed | 3 | 460 | Europe, RoW | Tenofovir + lamivudine + raltegravir, Tenofovir + lamivudine + efavirenz | ANRS, Emerging Infectious Diseases, Merck Sharp & Dohme LLC, Ministry of Health, Brazil | HIV-1 Infection, Tuberculosis | 11/18 | 11/18 | | |
